Citi initiated coverage of Neurocrine with a Neutral rating and $127 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Neurocrine receives FDA Breakthrough Therapy designation for crinecerfont
- Neurocrine price target raised to $139 from $134 at JPMorgan
- Neurocrine announces settlement of INGREZZA ANDA litigation
- Neurocrine price target lowered to $121 from $128 at RBC Capital